HRP20120549T1 - Derivati tienopiridona kao amp aktivirani aktivatori protein kinaze ampk - Google Patents

Derivati tienopiridona kao amp aktivirani aktivatori protein kinaze ampk Download PDF

Info

Publication number
HRP20120549T1
HRP20120549T1 HRP20120549AT HRP20120549T HRP20120549T1 HR P20120549 T1 HRP20120549 T1 HR P20120549T1 HR P20120549A T HRP20120549A T HR P20120549AT HR P20120549 T HRP20120549 T HR P20120549T HR P20120549 T1 HRP20120549 T1 HR P20120549T1
Authority
HR
Croatia
Prior art keywords
pyridin
hydroxy
thieno
dihydro
phenyl
Prior art date
Application number
HRP20120549AT
Other languages
English (en)
Croatian (hr)
Inventor
Daniel@Cravo
Franck@Lepifre
Sophie@Hallakou@Bozec
Christine@Charon
Original Assignee
Merck@Patent@GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40756916&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20120549(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck@Patent@GmbH filed Critical Merck@Patent@GmbH
Publication of HRP20120549T1 publication Critical patent/HRP20120549T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
HRP20120549AT 2008-05-05 2009-04-08 Derivati tienopiridona kao amp aktivirani aktivatori protein kinaze ampk HRP20120549T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08290423 2008-05-05
PCT/EP2009/002606 WO2009135580A1 (en) 2008-05-05 2009-04-08 Thienopyridone derivatives as amp-activated protein kinase (ampk) activators

Publications (1)

Publication Number Publication Date
HRP20120549T1 true HRP20120549T1 (hr) 2012-07-31

Family

ID=40756916

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20120549AT HRP20120549T1 (hr) 2008-05-05 2009-04-08 Derivati tienopiridona kao amp aktivirani aktivatori protein kinaze ampk

Country Status (26)

Country Link
US (1) US8604202B2 (https=)
EP (1) EP2280952B1 (https=)
JP (1) JP5536757B2 (https=)
KR (2) KR20160038065A (https=)
CN (1) CN102015676B (https=)
AR (1) AR071530A1 (https=)
AU (1) AU2009243811B2 (https=)
BR (1) BRPI0910832B8 (https=)
CA (1) CA2723429C (https=)
CO (1) CO6331304A2 (https=)
CY (1) CY1113112T1 (https=)
DK (1) DK2280952T3 (https=)
EA (1) EA020773B1 (https=)
EC (1) ECSP10010654A (https=)
ES (1) ES2388485T3 (https=)
HR (1) HRP20120549T1 (https=)
IL (1) IL208988A (https=)
MX (1) MX2010011916A (https=)
MY (1) MY160357A (https=)
NZ (1) NZ589690A (https=)
PL (1) PL2280952T3 (https=)
PT (1) PT2280952E (https=)
SI (1) SI2280952T1 (https=)
UA (1) UA103617C2 (https=)
WO (1) WO2009135580A1 (https=)
ZA (1) ZA201008722B (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US20130085169A1 (en) 2010-04-02 2013-04-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions comprising ampk activator (metformin/troglitazone) for the treatment of myotonic dystrophy type 1 (dm1)
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
JP5990170B2 (ja) * 2010-09-01 2016-09-07 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 除草活性を有するケトスルタム類及びジケトピリジン類
CA2830706A1 (en) * 2011-03-07 2012-09-13 Glaxosmithkline Llc Quinolinone derivatives
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
EP2679591A1 (en) 2012-06-29 2014-01-01 Poxel Thienopyridone derivatives useful as activators of AMPK
JP6064062B2 (ja) 2013-03-15 2017-01-18 ファイザー・インク Ａｍｐｋを活性化させるインダゾール化合物
US10143703B2 (en) 2014-01-02 2018-12-04 Massachusetts Eye And Ear Infirmary Treating ocular neovascularization
WO2015114663A1 (en) 2014-01-30 2015-08-06 Council Of Scientific & Industrial Research Novel thieno [2,3-d]pyrimidin-4(3h)-one compounds with antimycobacterial properties
WO2016205534A1 (en) * 2015-06-16 2016-12-22 Lazo John S Inhibitors of ptp4a3 for the treatment of cancer
RS61919B1 (sr) 2015-06-25 2021-06-30 Univ Health Network Inhibitori hpk1 i postupci za njihovo korišćenje
WO2017055925A2 (en) 2015-09-30 2017-04-06 Instituto De Medicina Molecular Methods for attenuating parasite virulence
US11584755B2 (en) 2017-09-26 2023-02-21 Ideaya Biosciences, Inc. Dihydrothieno[3,2-b]pyridine compounds
WO2019106087A1 (en) * 2017-11-29 2019-06-06 Syddansk Universitet Ampk inhibitors
WO2021236617A1 (en) 2020-05-19 2021-11-25 Kallyope, Inc. Ampk activators
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
EP4221700A1 (en) 2020-09-30 2023-08-09 Bioverativ Therapeutics Inc. Ampk activators and methods of use thereof
WO2022106892A1 (en) 2020-11-17 2022-05-27 Instituto De Medicina Molecular Anti-malarial compounds
JP2024540522A (ja) 2021-11-19 2024-10-31 ザ・ブロード・インスティテュート・インコーポレイテッド キナーゼを標的結合部分で標識するための二官能性キメラ分子及びその使用方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8627698D0 (en) * 1986-11-20 1986-12-17 Boots Co Plc Therapeutic agents
DE4444815A1 (de) 1994-12-15 1996-06-20 Merck Patent Gmbh Thienopyridone
AR040123A1 (es) 2002-05-31 2005-03-16 Upjohn Co Compuestos tiofeno, antihelminticos e insecticidas
US7119205B2 (en) * 2003-05-16 2006-10-10 Abbott Laboratories Thienopyridones as AMPK activators for the treatment of diabetes and obesity
WO2006093518A2 (en) * 2004-06-25 2006-09-08 Apath, Llc Thienyl compounds for treating virus-related conditions
US7563813B2 (en) * 2005-05-13 2009-07-21 Wyeth Iminothiazolidinone derivatives as SFRP-1 antagonists
EP1754483A1 (en) 2005-08-18 2007-02-21 Merck Sante Use of thienopyridone derivatives as AMPK activators and pharmaceutical compositions containing them
WO2007072094A1 (en) * 2005-12-20 2007-06-28 Richter Gedeon Nyrt. New compounds
MY155836A (en) * 2008-04-11 2015-12-15 Merck Patent Gmbh Thienopyridone derivatives as amp-activated protein kinase (ampk) activators

Also Published As

Publication number Publication date
IL208988A0 (en) 2011-01-31
EA020773B1 (ru) 2015-01-30
BRPI0910832B1 (pt) 2020-09-15
DK2280952T3 (da) 2012-07-23
KR20160038065A (ko) 2016-04-06
PT2280952E (pt) 2012-09-28
EA201001733A1 (ru) 2011-06-30
JP2011519876A (ja) 2011-07-14
KR101648593B1 (ko) 2016-08-16
ECSP10010654A (es) 2011-01-31
MY160357A (en) 2017-02-28
WO2009135580A1 (en) 2009-11-12
BRPI0910832A8 (pt) 2016-07-12
MX2010011916A (es) 2010-11-26
AU2009243811B2 (en) 2014-04-10
EP2280952B1 (en) 2012-06-27
ZA201008722B (en) 2012-01-25
PL2280952T3 (pl) 2012-10-31
CA2723429C (en) 2016-10-11
US8604202B2 (en) 2013-12-10
CN102015676A (zh) 2011-04-13
BRPI0910832A2 (pt) 2015-08-11
EP2280952A1 (en) 2011-02-09
CO6331304A2 (es) 2011-10-20
CY1113112T1 (el) 2016-04-13
HK1156313A1 (en) 2012-06-08
JP5536757B2 (ja) 2014-07-02
AR071530A1 (es) 2010-06-23
ES2388485T3 (es) 2012-10-15
CN102015676B (zh) 2014-05-28
US20110060001A1 (en) 2011-03-10
IL208988A (en) 2016-02-29
AU2009243811A1 (en) 2009-11-12
UA103617C2 (ru) 2013-11-11
SI2280952T1 (sl) 2012-09-28
CA2723429A1 (en) 2009-11-12
KR20110010757A (ko) 2011-02-07
NZ589690A (en) 2012-07-27
BRPI0910832B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
HRP20120549T1 (hr) Derivati tienopiridona kao amp aktivirani aktivatori protein kinaze ampk
JP2011519876A5 (https=)
JP2011516510A5 (https=)
ES2529226T3 (es) Nuevos componentes que se unen a FXR (NR1H4) y modulan su actividad
ME02537B (me) Derivati tienopiridona korisni kao ampk aktivatori
RS53710B2 (sr) Jedinjenja kao antagonisti b1 bradikinina
CA2532067A1 (en) N-methyle-substituted benzamidazoles
NZ598294A (en) Heterocyclic compounds for the inhibition of pask
FI3738434T3 (fi) Välituotteita substituoitujen bentsaldehydiyhdisteiden saamiseksi ja menetelmiä niiden käyttöön kudosten hapetuksen lisäämiseksi
MX375261B (es) Compuestos aromaticos sustituidos para el tratamiento de la fibrosis pulmonar, la fibrosis hepatica, la fibrosis de la piel y la fibrosis cardiaca.
HRP20161103T1 (hr) Kemijski spojevi
HRP20180176T1 (hr) Spojevi korisni u sintezi spojeva benzamida
EP0679157A1 (en) Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents
RU2015115278A (ru) Производные гидропирролопиррола для применения в качестве ингибиторов синтазы жирных кислот
ME02312B (me) DERIVATI PIRAZOLOSPIROKETONA, NAMIJENJENI UPOTREBI KAO INHIBITORI ACETIL-CoA-KARBOKSILAZE
EP1654247A1 (en) Alkynyl aryl carboxamides
JP2014517001A5 (https=)
RU2017109814A (ru) Кристаллическая 7-{ (3s,4s)-3-[(циклопропиламино)метил]-4-фторпирролидин-1-ил} -6-фтор-1-(2-фторэтил)-8-метокси-4-оксо-1,4-дигидрохинолин-3-карбоновая кислота
CA2726005C (en) Process for the preparation of halogenated benzoic acid derivatives
HRP20161196T1 (hr) Modulatori jetrenog receptora x
CN102000054B (zh) 一种黄酮类似物、制备及其作为抗糖尿病药物的用途
CN102503825A (zh) 药物中间体丁酮二酸二酯类化合物的制备方法
EG26411A (en) Catalyst for reacting carboxylic acid nitriles
JP2013536164A5 (https=)
CN105294476B (zh) 2‑酰氧基丙烯酰胺类化合物的合成方法